Leonard Kamen, DO
Physical Medicine & Rehabilitation · Elkins Park, PANPI 1760577324
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,980 of the $44,444 with a category attached, or 76.5%. Biodelivery Sciences International, Inc. accounts for 70.7% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $36,100 and has fallen 99.6% since, to $130 in 2025. Among physical medicine & rehabilitation clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $290.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biodelivery Sciences International, Inc.$31K
- Indivior Inc.$7K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Biohaven Pharmaceuticals, Inc.$1K
- Collegium Pharmaceutical, Inc.$465
- AbbVie$332
- plus $899 from 18 others
What the payments were for
- Consulting fees$1,2003%
- Speaking & faculty fees$33,98076%
- Travel & lodging$5,80113%
- Food & beverage$3,4648%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biodelivery Sciences International, Inc. | 45 | $31,437 |
| Indivior Inc. | 16 | $7,196 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $2,834 |
| Biohaven Pharmaceuticals, Inc. | 3 | $1,281 |
| Collegium Pharmaceutical, Inc. | 25 | $465 |
| AbbVie(2 entities) | 19 | $332 |
| Lilly USA, LLC | 11 | $252 |
| Ipsen Biopharmaceuticals, Inc | 1 | $103 |
| Avanir Pharmaceuticals, Inc. | 7 | $103 |
| GRT US Holding, Inc. | 2 | $65 |
| Amgen | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Protega Pharmaceutials Inc | 2 | $42 |
| Radius Health, Inc. | 2 | $36 |
| Almatica Pharma LLC | 1 | $27 |
| Vertex | 1 | $25 |
| Pacira Pharmaceuticals Incorporated | 1 | $25 |
| MDD US Operations, LLC | 1 | $24 |
| Pfizer | 1 | $22 |
| Biogen | 1 | $22 |
| Heron Therapeutics, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Forte Bio-pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,444 in reported general payments places this provider in the 95th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
See all physical medicine & rehabilitation providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 154 | $150,564 |
| NucyntaTapentadol Hcl | 74 | $128,349 |
| Nucynta ErTapentadol Hcl | 40 | $68,883 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 405 | $60,250 |
| Buprenorphine | 221 | $57,373 |
| Xtampza ErOxycodone Myristate | 74 | $46,321 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 68 | $40,493 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 332 | $25,393 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 537 | $13,818 |
| TrintellixVortioxetine Hydrobromide | 20 | $9,823 |
| Emgality SyringeGalcanezumab-Gnlm | 14 | $9,603 |
| Oxycodone Hcl | 534 | $9,086 |
| Gabapentin | 560 | $7,236 |
| Tizanidine Hcl | 319 | $6,042 |
| ButransBuprenorphine | 15 | $5,837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Nucynta Er, Xtampza Er | $465 | $394,116342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
Other physical medicine & rehabilitation in Elkins Park
- Michael SaulinoElkins Park$425K
- Daniel MoonElkins Park$7K
- Jeffery RoweKing Of Prussia$1.9M
- Huaguang QuChalfont$356K
- Alberto EsquenaziPhiladelphia$305K
- Mitchell PaulinPaoli$229K
- Kimberly HeckertPhiladelphia$119K
- David LichtenReading$117K
- Gay WilcherRidley Park$81K
- Jessica MulhernPaoli$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.